Biologic/immunomodulator therapy
Biologics and targeted immunomodulators (anti-TNF: infliximab, adalimumab, etanercept; other bDMARDs: rituximab, tocilizumab, vedolizumab, ustekinumab; JAK inhibitors: tofacitinib, baricitinib) increase susceptibility to infection. Anti-TNF agents particularly associated with higher infection rates and TB reactivation risk. DENTAL TAKEAWAY: most routine dentistry proceeds normally; urgent infections treated promptly and aggressively; big issues are infection risk, timing around surgery, and drug interactions. Biologics do NOT automatically require antibiotic prophylaxis.
The full condition entry includes
- Safe vs avoid lists: antibiotics, analgesics, local anesthetics
- Vasoconstrictor limits and treatment modifications
- Pre/intra/post-op monitoring and deferral criteria
- Emergency management, explained for study
More medical conditions in dentistry
Dentalverse is an educational resource for dental students and dentists. This page is a study reference — it is not medical advice and does not replace clinical judgment. Always follow your institution's protocols and your supervisor's guidance.